Mwazyunga Z, Ambrose E, Kayange N, Bakalemwa R, Kidenya B, Smart L
Open J Blood Dis. 2023; 12(2):11-28.
PMID: 38031542
PMC: 10686543.
DOI: 10.4236/ojbd.2022.122002.
Bakshi N, Astles R, Chou E, Hurreh A, Sil S, Sinha C
Pediatr Blood Cancer. 2022; 70(1):e30046.
PMID: 36322607
DOI: 10.1002/pbc.30046.
Abadesso C, Pacheco S, Machado M, Finley G
Children (Basel). 2022; 9(2).
PMID: 35205003
PMC: 8870385.
DOI: 10.3390/children9020283.
Ragab I, Ellabody M, Ramy H, Mahmoud N, Sayed S
Indian J Hematol Blood Transfus. 2021; 37(4):616-622.
PMID: 34690455
PMC: 8523600.
DOI: 10.1007/s12288-021-01396-y.
Porter J, Paladino A, Russell K, Rupff R, Griffith J, Mai Y
J Pediatr Psychol. 2021; 47(1):75-85.
PMID: 34432048
PMC: 9020477.
DOI: 10.1093/jpepsy/jsab079.
Assessing quality of life in pediatric fibrous dysplasia and McCune Albright syndrome: PEDS-QL and HADS data from the Fibrous Dysplasia Foundation Patient Registry.
Konradi A
J Patient Rep Outcomes. 2021; 5(1):34.
PMID: 33846865
PMC: 8042095.
DOI: 10.1186/s41687-021-00304-2.
What is the future of patient-reported outcomes in sickle-cell disease?.
Singh S, Bakshi N, Mahajan P, Morris C
Expert Rev Hematol. 2020; 13(11):1165-1173.
PMID: 33034214
PMC: 7722233.
DOI: 10.1080/17474086.2020.1830370.
Quality of Life of Latino and Non-Latino Youth With Sickle Cell Disease as Reported by Parents and Youth.
Osborne J, Green N, Smaldone A
Hisp Health Care Int. 2020; 18(4):224-231.
PMID: 32124643
PMC: 7483779.
DOI: 10.1177/1540415320908525.
End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.
Farrell A, Panepinto J, Carroll C, Darbari D, Desai A, King A
Blood Adv. 2019; 3(23):3982-4001.
PMID: 31809538
PMC: 6963237.
DOI: 10.1182/bloodadvances.2019000882.
Clinical meaning of PROMIS pain domains for children with sickle cell disease.
Singh A, Panepinto J
Blood Adv. 2019; 3(15):2244-2249.
PMID: 31345791
PMC: 6693018.
DOI: 10.1182/bloodadvances.2019000381.
Appraisal of patient-reported outcome measures in analogous diseases and recommendations for use in phase II and III clinical trials of pyruvate kinase deficiency.
Salek M, Ionova T, Johns J, Oliva E
Qual Life Res. 2018; 28(2):399-410.
PMID: 30456713
PMC: 6373289.
DOI: 10.1007/s11136-018-2025-y.
Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy.
Strauss K, Carson V, Brigatti K, Young M, Robinson D, Hendrickson C
J Pediatr Orthop. 2018; 38(10):e610-e617.
PMID: 30134351
PMC: 6211782.
DOI: 10.1097/BPO.0000000000001247.
Systematic literature review and assessment of patient-reported outcome instruments in sickle cell disease.
Sarri G, Bhor M, Abogunrin S, Farmer C, Nandal S, Halloway R
Health Qual Life Outcomes. 2018; 16(1):99.
PMID: 29784054
PMC: 5963009.
DOI: 10.1186/s12955-018-0930-y.
Pain catastrophizing is associated with poorer health-related quality of life in pediatric patients with sickle cell disease.
Bakshi N, Lukombo I, Belfer I, Krishnamurti L
J Pain Res. 2018; 11:947-953.
PMID: 29773954
PMC: 5947835.
DOI: 10.2147/JPR.S151198.
HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.
Smaldone A, Findley S, Manwani D, Jia H, Green N
J Pediatr. 2018; 197:177-185.e2.
PMID: 29571930
PMC: 5970970.
DOI: 10.1016/j.jpeds.2018.01.054.
Family Functioning, Medical Self-Management, and Health Outcomes Among School-Aged Children With Sickle Cell Disease: A Mediation Model.
Psihogios A, Daniel L, Tarazi R, Smith-Whitley K, Patterson C, Barakat L
J Pediatr Psychol. 2017; 43(4):423-433.
PMID: 29048590
PMC: 6927851.
DOI: 10.1093/jpepsy/jsx120.
Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Smaldone A, Findley S, Bakken S, Matiz L, Rosenthal S, Jia H
Contemp Clin Trials. 2016; 49:134-42.
PMID: 27327779
PMC: 5024731.
DOI: 10.1016/j.cct.2016.06.004.
Responsiveness of PROMIS® Pediatric Measures to Hospitalizations for Sickle Pain and Subsequent Recovery.
Dampier C, Jaeger B, Gross H, Barry V, Edwards L, Lui Y
Pediatr Blood Cancer. 2016; 63(6):1038-45.
PMID: 26853841
PMC: 5055833.
DOI: 10.1002/pbc.25931.
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.
Brousseau D, Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G
Blood. 2015; 126(14):1651-7.
PMID: 26232172
PMC: 4591790.
DOI: 10.1182/blood-2015-05-647107.
Lessons Learned From a Randomized Controlled Trial of a Family-Based Intervention to Promote School Functioning for School-Age Children With Sickle Cell Disease.
Daniel L, Li Y, Smith K, Tarazi R, Robinson M, Patterson C
J Pediatr Psychol. 2015; 40(10):1085-94.
PMID: 26136404
PMC: 4626743.
DOI: 10.1093/jpepsy/jsv063.